299,180 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 299,180 shares of the company’s stock, valued at approximately $4,476,000. Lisanti Capital Growth LLC owned about 0.20% of Adaptive Biotechnologies at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in shares of Adaptive Biotechnologies by 45.8% during the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP bought a new stake in Adaptive Biotechnologies during the first quarter worth about $93,000. KLP Kapitalforvaltning AS boosted its holdings in shares of Adaptive Biotechnologies by 42.9% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 25,000 shares of the company’s stock worth $291,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Adaptive Biotechnologies by 9.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 32,038 shares of the company’s stock valued at $373,000 after purchasing an additional 2,880 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Up 0.7%

NASDAQ:ADPT opened at $18.50 on Friday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -34.26 and a beta of 2.18. The company has a fifty day moving average of $17.29 and a 200 day moving average of $14.97. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company’s revenue was up 102.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) EPS. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Buying and Selling

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 4,290 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00. Following the completion of the transaction, the chief financial officer owned 216,637 shares of the company’s stock, valued at $3,899,466. This represents a 1.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Francis Lo sold 79,590 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70. Following the completion of the sale, the insider owned 315,978 shares of the company’s stock, valued at approximately $5,602,289.94. This trade represents a 20.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,442,530 shares of company stock valued at $24,610,748 over the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ADPT. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.22.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.